Defence Therapeutics (TSE:DTC) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Defence Therapeutics Inc. has announced that its AccuTOX® technology not only kills tumors but also boosts the immune system, significantly enhancing the effectiveness of Immune Checkpoint Inhibitors (ICI) in treating solid tumors. AccuTOX® achieves this by converting ‘cold’ tumors, which typically resist ICI treatment, into ‘hot’ tumors that are more vulnerable to immune attack. The company has observed a tenfold increase in treatment efficacy in preclinical studies and sees AccuTOX® as a potential game-changer for increasing the patient population eligible for ICI treatment.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.